Tremelimumab: a review of development to date in solid tumors
- 1 March 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Immunotherapy
- Vol. 5 (3), 215-229
- https://doi.org/10.2217/imt.13.9
Abstract
Tremelimumab is an investigational, fully human IgG monoclonal antibody directed against CTLA-4, a coinhibitory receptor that represses effector T-cell activity in cancer. Tremelimumab has produced promising anticancer responses in early clinical trials. However, a phase III trial of tremelimumab monotherapy versus chemotherapy in advanced melanoma was stopped early when no statistically significant difference in overall survival was observed between the two interventions. This article describes tremelimumab's putative mechanism of action, its preclinical pharmacology and clinical results to date across a range of cancer settings as monotherapy, as well as in combination with other therapies. The failure of the Phase III trial in melanoma is examined and factors affecting the possible future clinical development of tremelimumab are also explored.This publication has 97 references indexed in Scilit:
- Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesCancer Immunology, Immunotherapy, 2011
- Targeting BRAF for patients with melanomaBritish Journal of Cancer, 2010
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel ImmunotherapySeminars in Oncology, 2010
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The complex role of B7 molecules in tumor immunologyTrends in Molecular Medicine, 2008
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?Clinical Cancer Research, 2008
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002